【摘要】 曾因食管或胃曲张静脉破裂出血的163例肝硬化患者被随机分成5组治疗:1.硝苯啶(nifedipine,NIF)组为31倒;2.维拉帕米(verapamil,VER)组28例;3.脑益嗪(cinnarizine,CIN)组29例;4.汉防己甲素(tetrandrine,TET)组33例以及5.普洛乃尔(propranolol,PRO)组42例。经18月治疗后各组未再发生消化道出血的病例数分别为:TET组达29例(87.9%),NIF组24例(74.2%),VER组18例(64.3%),CIN组17例(58.6%)及PRO组23例(54.8%)。结果说明钙通道阻滞剂TET似乎是当前预防肝硬化门脉高压患者食管静脉曲张破裂出血较为理想的药物。更多还原

【Abstract】 163 cirrhotic patients who had bled from esophageal or gastric varices were randomly assigned to 5 groups: 1st group of 31 patients receiving nifediping (NIF), 2nd group of 28 patients receving verapamil (VER), 3rd group of 29 patients receiving cinnarizine (CIN), 4th group of 33 patiens receiving tetrandrine (TET) and 5th group of 42 patients recieving propranolol (PRO). The proportion of patients free of recurrent gastrointestinal bleeding 18 months after inclusion in this study was 87.9% in TET group, 74.2% in NIF group, 64.3% in VER group, 58.60% in CIN group and 54.80% in PROP group (P<0.05). This study suggests that TET is more appropriate for preventing bleeding from esophageal or gastric varices in cirrhotic patients with portal hypertension at the present time.更多还原